FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology. Presented are method for producing an influenza virus vaccine and using a permanent human amniocyte cell for producing the influenza virus vaccine. The presented method involves infecting a permanent human amniocyte cell, culturing the amniocyte cell, expressing influenza virus, recovering the prepared influenza virus from the medium. The human amniocyte cell expresses the adenoviral gene products E1A and E1B. Using the permanent human amniocyte cells for producing the influenza virus vaccine enables using the influenza viruses, a phenotype of which are no different from wild-type viruses, for producing the vaccine that promotes generating the cell-mediated immunity in individuals.
EFFECT: presented method for producing the vaccine and using the permanent human amniocyte cell for producing the influenza virus vaccine may be used in medicine for producing effective influenza virus vaccines.
11 cl, 36 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONDITIONALLY DEFECTIVE PARTICLE OF INFLUENZA VIRUS AND METHODS OF PRODUCING THEREOF (VERSIONS) | 2005 |
|
RU2420577C2 |
| NOVEL CONSTANT LINE OF HUMAN CELLS | 2010 |
|
RU2569181C2 |
| BACULOVIRUS VECTOR AND USE THEREOF | 2007 |
|
RU2588464C2 |
| PASSAGE VECTOR AND VACCINE FOR TUBERCULOSIS | 2007 |
|
RU2453603C2 |
| METHOD FOR PRODUCING REPLICATIVE INFLUENZA VIRUS PARTICLES, CELL COMPOSITION (VERSIONS), CELL CULTURE COMPOSITION AND APPLICATION THEREOF | 2005 |
|
RU2435855C2 |
| FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPs) | 2006 |
|
RU2483751C2 |
| DNA STRUCTURE (VARIANTS), DNA-VECTOR, IMMUNOGENIC COMPOSITION AGAINST INFLUENZA VIRUS, METHOD OF IMMUNE RESPONSE INDUCTION, VACCINE AND METHOD OF VACCINATION | 1994 |
|
RU2193065C2 |
| FLU VIRUS PROTEINS PRODUCER MDCK CELL (OPTIONS) | 2018 |
|
RU2681482C1 |
| IMMORTALIZED CHICKEN EMBRYO FIBROBLASTS | 2015 |
|
RU2694318C2 |
| MULTIVALENT INFLUENZA VACCINE | 2018 |
|
RU2706191C1 |
